In this randomized controlled experimental medicine study, we tested the hypothesis that COVID‐19‐associated coagulopathy is partly driven by RAAS dysregulation by measuring the response on D‐dimer of a biased agonist at the AGTR1 in hospitalized COVID‐19 patients. Here, AGTR1 is linked to blood coagulation disease.